Card kit

Invitae Disorders of Female Sex Development Test

Test code: 04413 •

Test description

The Invitae Disorders of Female Sex Development test analyzes the SRY gene that is associated with 46,XX disorders of sex development (DSD)/complete gonadal dysgenesis (CGD). This test can be used determine the presence or absence of the SRY gene in a phenotypic male individual who presents with a female karyotype of 46,XX.

Genetic testing of SRY may confirm a diagnosis and help guide clinical management decisions. Identification of a disease-causing variant can inform recurrence-risk assessment and genetic counseling.

Disorders tested

46,XX Disorders of Sex Development (DSD)/Complete Gonadal Dysgenesis (CGD)

Ordering information

Turnaround time:

10–21 calendar days (14 days on average)

New York approved:

Yes

Preferred specimen:

3mL whole blood in a purple-top EDTA tube (K2EDTA or K3EDTA)

Alternate specimens:

Saliva, buccal swab, and gDNA are also accepted.Learn more about specimen requirementsRequest a specimen collection kit

Clinical description and sensitivity

Clinical description:

Patients with 46,XX disorders of sex development (46,XX DSD) have a 46,XX chromosomal complement but are phenotypically male. This disorder is characterized by azoospermia, absence of female Müllerian structures, and male external genitalia that can range from normal to ambiguous. Small testes, gynecomastia, and testosterone deficiency are also observed. If testosterone deficiency is left untreated, patients may also experience erectile dysfunction, sparse body hair, reduced muscle mass, and increased in fat mass; they may also have increased risks for osteopenia and depression.

Clinical description and sensitivity

Clinical description:

Patients with 46,XX disorders of sex development (46,XX DSD) have a 46,XX chromosomal complement but are phenotypically male. This disorder is characterized by azoospermia, absence of female Müllerian structures, and male external genitalia that can range from normal to ambiguous. Small testes, gynecomastia, and testosterone deficiency are also observed. If testosterone deficiency is left untreated, patients may also experience erectile dysfunction, sparse body hair, reduced muscle mass, and increased in fat mass; they may also have increased risks for osteopenia and depression.


Clinical sensitivity:


The SRY gene is the principal gene associated with 46,XX testicular DSD and accounts for approximately 80% of affected individuals. Alterations of SRY are a rare cause of 46,XY DSD but cause up to 15% of 46,XY CGD.

Assay information

Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).

Our sequence analysis covers clinically important regions of each gene, including coding exons and 10 to 20 base pairs of adjacent intronic sequence on either side of the coding exons in the transcript listed below, depending on the specific gene or test. In addition, the analysis covers select non-coding variants. Any variants that fall outside these regions are not analyzed. Any limitations in the analysis of these genes will be listed on the report. Contact client services with any questions.

Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. In very rare cases, (circulating hematolymphoid neoplasm, bone marrow transplant, recent blood transfusion) the analyzed DNA may not represent the patient's constitutional genome.

Assay information

Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).

Our sequence analysis covers clinically important regions of each gene, including coding exons and 10 to 20 base pairs of adjacent intronic sequence on either side of the coding exons in the transcript listed below, depending on the specific gene or test. In addition, the analysis covers select non-coding variants. Any variants that fall outside these regions are not analyzed. Any limitations in the analysis of these genes will be listed on the report. Contact client services with any questions.

Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. In very rare cases, (circulating hematolymphoid neoplasm, bone marrow transplant, recent blood transfusion) the analyzed DNA may not represent the patient's constitutional genome.

Order test

You can customize this test by clicking genes to remove them.

Primary panel

1 gene selected
SRY

Question about billing? 

Find answers